New test can ID patients at risk of severe COVID-19, study finds uva frontiersin
Longitudinal gene expression analysis over 72 hours after admission to the ICU revealed that the immune profiles of COVID and non-COVID AHRF patients remained largely unchanged over time. However, among the COVID-19-induced AHRF patients, profiles of COVID Group 1 patients appeared to exhibit greater changes than COVID Group 2.
We have applied a combination of bioinformatics approaches to characterize COVID-19 patients based on disease stage and severity using gene expression data, but must acknowledge the limitations of the data. Our initial dataset of ICU patients contained up to 13 patients per cohort and COVID-19 patients were also sub-divided into groups, which reduced the statistical power of our analyses.
Overall, we have identified immune profiles of severe COVID-19 patients associated with full recovery from disease or increased risk of mortality. We propose that these differences in COVID Group 1 and Group 2 patients could be employed to better allocate healthcare resources and design targeted treatment plans to better care for individuals who are at the greatest risk of worse outcomes.
The studies involving human participants were reviewed and approved by UVA Institutional Review Board for Health Sciences Research. The patients/participants provided their written informed consent to participate in this study.Conceptualization: CB, LS, JS, AG, AK, and PL. Methodology: CB, LS, JS, AK, and PL. Software: PB. Formal Analysis: AD and PB. Data Curation: PB, CB, LS, JS, and AK. Writing – Original Draft: AD. Writing – Review & Editing, AD, CB, LS, JS, AK, and PL. Visualization: AD.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A living WHO guideline on drugs for covid-19Updates This is the twelfth version (eleventh update) of the living guideline, replacing earlier versions (available as data supplements). New recommendations will be published as updates to this guideline. Clinical question What is the role of drugs in the treatment of patients with covid-19? Context The evidence base for therapeutics for covid-19 is evolving with numerous randomised controlled trials (RCTs) recently completed and under way. The emerging SARS-CoV-2 variants (such as omicron) and subvariants are also changing the role of therapeutics. This update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers, and janus kinase (JAK) inhibitors in patients with severe or critical covid-19, and modifies previous recommendations for the neutralising monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe covid-19. New or updated recommendations • Remdesivir: a conditional recommendation for its use in patients with severe covid-19; and a conditional recommendation against its use in patients with critical covid-19. • Concomitant use of IL-6 receptor blockers (tocilizumab or sarilumab) and the JAK inhibitor baricitinib: these drugs may now be combined, in addition to corticosteroids, in patients with severe or critical covid-19. • Sotrovimab and casirivimab-imdevimab: strong recommendations against their use in patients with covid-19, replacing the previous conditional recommendations for their use. Understanding the new recommendations When moving from new evidence to updated recommendations, the Guideline Development Group (GDG) considered a combination of evidence assessing relative benefits and harms, values and preferences, and feasibility issues. For remdesivir, new trial data were added to a previous subgroup analysis and provided sufficiently trustworthy evidence to demonstrate benefits in patients with severe covid-19, but not c
Read more »
COVID-19's future is uncertain as infections increase and tracking decreasesCOVID-19's future is uncertain as infections increase and tracking decreases Coronavirus Disease COVID19 Evolution Omicron BA4 BA5 viral surveillance SARSCoV2 VirusesMDPI montanastate BozemanHealth
Read more »
New report details global COVID-19 response failures, calls for improved multilateral cooperationWidespread, global failures at multiple levels in the COVID-19 response led to millions of preventable deaths and reversed progress made towards the UN Sustainable Development Goals (SDGs) in many countries, according to a new report from The Lancet Commission.
Read more »
The World Health Organisation says the end of the Covid-19 pandemic is “in sight”Global deaths from Covid-19 have fallen to their lowest level since March 2020, the organisation revealed.
Read more »
Buses to be reviewed as routes still below pre-Covid levelsChanging work patterns, online shopping and the 'legacy of Covid' are cited as factors.
Read more »